---
title: "Brawn Biotech Ltd (530207) — Share Price, Financials & Analysis"
symbol: "530207"
company: "Brawn Biotech Ltd"
canonical: "https://tapetide.com/stocks/530207"
isin: "INE899B01015"
nse_symbol: "BRAWNPHARMACEUTICALSLTD"
bse_code: "530207"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 7
generated_at: "2026-09-13T19:31:27.467Z"
---

# Brawn Biotech Ltd (530207)

Canonical page: https://tapetide.com/stocks/530207

## Company

- **NSE Symbol:** BRAWNPHARMACEUTICALSLTD
- **BSE Code:** 530207
- **ISIN:** INE899B01015
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** brawnbiotech.com

## About

Incorporated in 1985, Brawn Biotech Ltd is in the business of trading pharmaceutical products[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:36:42.543867Z.

- **Market Cap:** ₹7 Cr
- **Classification:** Microcap
- **P/E (reported):** 8.1
- **EPS (TTM):** ₹2.83
- **EPS (reported):** ₹0.62
- **Book Value:** ₹14.46
- **Price to Book:** 1.61
- **Dividend Yield:** 0%
- **ROE:** 21.68%
- **ROCE:** 0.1%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹17.4 Cr
- **Net Income:** ₹0.9 Cr
- **EBITDA:** ₹0.1 Cr
- **52-Week High:** ₹24.37
- **52-Week Low:** ₹17.71
- **RSI (14):** 58.14

## Tapetide Score

- **Score:** 55 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Fair · Momentum: Rising
- **Percentile:** 70.1 (of 4473 scored stocks)
- **Confidence:** 98%
- **Data coverage:** 95%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 45.49 | 9% |
| growth | 57.38 | 9% |
| momentum | 72.23 | 12% |
| ownership | 50 | 24% |
| quality | 48.97 | 22% |
| valuation | 59.58 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company's working capital requirements have reduced from 130 days to 35.9 days

### Weaknesses

- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -13.5% over past five years.
- Company has a low return on equity of -14.8% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | — | — | 305.26% |
| ebitda margin growth | -100% | -105.89% | -108.4% | -103.15% |
| net income growth | -100% | -152.94% | 46% | 30% |
| revenue growth | -75% | 27.94% | -9% | -13% |
| roce | — | -100.62% | -100.52% | -13.76% |
| roe | — | -141.89% | -18.23% | -195.21% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 2.92 | 2.84 | 3.45 | 4.06 | 3.3 | 3.84 | 2.26 | 5.8 | 4.89 | 4.31 | 1.98 | 6.08 |
| Expenses | 3.31 | 3.42 | 3.84 | 4.56 | 3.62 | 4.24 | 2.81 | 5.62 | 4.88 | 4.32 | 2.49 | 6.04 |
| Operating Profit | -0.39 | -0.58 | -0.39 | -0.5 | -0.32 | -0.4 | -0.55 | 0.18 | 0.01 | -0.01 | -0.51 | 0.04 |
| OPM % | -13.36 | -20.42 | -11.3 | -12.32 | -9.7 | -10.42 | -24.34 | 3.1 | 0.2 | -0.23 | -25.76 | 0.66 |
| Other Income | 0 | 0 | 0.08 | 0 | 0 | 0 | 0.09 | 0.09 | 0.09 | 0.09 | 0.18 | 0.14 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| Profit before tax | -0.42 | -0.61 | -0.34 | -0.53 | -0.35 | -0.43 | -0.49 | 0.24 | 0.07 | 0.05 | -0.36 | 0.15 |
| Tax % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -261.11 | 0 |
| Net Profit | -0.42 | -0.61 | -0.34 | -0.53 | -0.34 | -0.43 | -0.49 | 0.24 | 0.07 | 0.05 | 0.58 | 0.15 |
| EPS in Rs | -1.4 | -2.03 | -1.13 | -1.77 | -1.13 | -1.43 | -1.63 | 0.8 | 0.23 | 0.17 | 1.93 | 0.5 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 55.71 | 65.18 | 49.62 | 34.98 | 8.53 | 22.23 | 16.49 | 13.46 | 16.98 | 17.26 |
| Expenses | 53.75 | 64.01 | 48.89 | 35.58 | 10.53 | 22.53 | 17.95 | 15.23 | 17.31 | 17.73 |
| Operating Profit | 1.96 | 1.17 | 0.73 | -0.6 | -2 | -0.3 | -1.46 | -1.77 | -0.33 | -0.47 |
| OPM % | 3.52 | 1.8 | 1.47 | -1.72 | -23.45 | -1.35 | -8.85 | -13.15 | -1.94 | -2.72 |
| Other Income | 0.09 | 0.74 | 0.17 | 0.31 | 0 | 0.01 | 0.08 | 0.09 | 0.45 | 0.5 |
| Interest | 0.06 | 0.07 | 0.05 | 0.04 | 0.06 | 0.01 | 0.06 | 0 | 0 | 0 |
| Depreciation | 0.03 | 0.03 | 0.03 | 0.03 | 0.05 | 0.11 | 0.1 | 0.11 | 0.12 | 0.12 |
| Profit before tax | 1.96 | 1.81 | 0.82 | -0.36 | -2.11 | -0.41 | -1.54 | -1.79 | 0 | -0.09 |
| Tax % | 34.69 | 26.52 | 28.05 | 55.56 | -22.27 | 109.76 | -19.48 | -3.35 | — | — |
| Net Profit | 1.28 | 1.33 | 0.59 | -0.55 | -1.64 | -0.87 | -1.25 | -1.74 | 0.94 | 0.85 |
| EPS in Rs | 4.27 | 4.43 | 1.97 | -1.83 | -5.47 | -2.9 | -4.17 | -5.8 | 3.13 | 2.83 |
| Dividend Payout % | 23.44 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Reserves | 3.92 | 4.63 | 5.66 | 6.26 | 5.79 | 4.22 | 3.31 | 2.06 | 0.36 | 1.34 |
| Borrowings | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities | 10.11 | 14.94 | 13.85 | 11.03 | 5.08 | 6.56 | 8.22 | 9.53 | 17.13 | 16.52 |
| Total Liabilities | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 | 20.86 |
| Fixed Assets | 0.25 | 0.22 | 0.19 | 0.18 | 0.14 | 0.39 | 0.37 | 0.33 | 0.46 | 0.36 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 16.78 | 22.35 | 22.32 | 20.11 | 13.73 | 13.39 | 14.16 | 14.26 | 20.03 | 20.5 |
| Total Assets | 17.03 | 22.57 | 22.51 | 20.29 | 13.87 | 13.78 | 14.53 | 14.59 | 20.49 | 20.86 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1.37 | -1.54 | 0.21 | -0.08 | 0.03 | 0.19 | 0.32 | -0.03 | 0.05 | 0.77 |
| Cash from Investing Activity | 0.57 | 0 | 0 | -0.02 | 0 | -0.3 | -0.1 | -0.01 | -0.24 | -0.03 |
| Cash from Financing Activity | -0.11 | -0.06 | -0.06 | -0.05 | -0.04 | -0.06 | -0.01 | 0 | 0 | 0 |
| Net Cash Flow | 1.83 | -1.6 | 0.15 | -0.14 | 0 | -0.17 | 0.21 | -0.04 | -0.2 | 0.74 |
| Free Cash Flow | 1.34 | -1.54 | 0.21 | -0.1 | 0.03 | -0.11 | 0.22 | -0.04 | -0.19 | 0.74 |
| CFO/OP | 170 | -14 | 88 | 21 | -52 | -10 | -103 | 2 | -3 | -233 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 79.5 | 98.6 | 92.17 | 110.34 | 96.83 | 120.24 | 87.35 | 85.88 | 92.47 | 76.31 |
| Inventory Days | 2.59 | 2.62 | 2.12 | 3.38 | 3.16 | 261.82 | 91.2 | 153.02 | 320.33 | 253.06 |
| Days Payable | 47.7 | 83.93 | 64.58 | 74.47 | 32.34 | 224.66 | 123.19 | 144.12 | 252.1 | 362.48 |
| Cash Conversion Cycle | 34.39 | 17.29 | 29.72 | 39.25 | 67.65 | 157.41 | 55.36 | 94.78 | 160.7 | -33.11 |
| Working Capital Days | 28.21 | 43.37 | 42.06 | 58.04 | 77.53 | 241.76 | 80.62 | 137.9 | 216.4 | 35.9 |
| ROCE % | 29.28 | 27.77 | 23.08 | 9.71 | -3.55 | -25.61 | -5.91 | -25.86 | -42.52 | 0 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 53.72% | 53.72% | 53.64% | 53.64% | 53.64% | 53.64% | 53.66% | 53.66% | 53.66% | 53.39% | 52.94% | 52.94% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.59% | 0.59% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% | 0.35% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 42.89% | 42.9% | 33.91% | 33.96% | 33.84% | 33.2% | 33.17% | 32.88% | 32.9% | 30.97% | 30.49% | 30.53% |
| Others | 2.8% | 2.79% | 12.1% | 12.05% | 12.17% | 12.81% | 12.82% | 13.11% | 13.09% | 15.29% | 16.22% | 16.18% |
| No. of Shareholders | 6194 | 6139 | 4160 | 4090 | 4157 | 4060 | 4024 | 3975 | 3958 | 3444 | 3303 | 3284 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 5 / 6

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 22.91 | Sell |
| EMA (10) | 22.88 | Sell |
| SMA (20) | 22.76 | Sell |
| EMA (20) | 22.62 | Sell |
| SMA (50) | 21.89 | Buy |
| EMA (50) | 22.01 | Buy |
| SMA (100) | 21.22 | Buy |
| EMA (100) | 21.51 | Buy |
| SMA (200) | 21.03 | Buy |
| EMA (200) | 21 | Buy |

### Oscillators — summary: **Neutral**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 47.38 | Neutral |
| MACD (12,26,9) | 0.37 | Sell |
| Stochastic (14,3,3) | 50.48 | Neutral |
| ADX (14) | 11.37 | Neutral |
| Williams %R (14) | -86.19 | Buy |
| ATR (14) | 0.64 | Neutral |
| ROC (12) | -3.74 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 48.5 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b6e18eac-1939-4803-b5b5-07fae6dfee67.pdf) |
| 2026-09-02 | [Intimation W.R.T Letter Sent To Shareholders As Per Reg 36](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=712cab3b-657b-40f7-851f-a1c65096b540.pdf) |
| 2026-09-01 | [Notice Of 41St AGM To Be Held On 29.09.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b88bfb9e-91c1-4977-b0e3-9471aa74c66b.pdf) |
| 2026-09-01 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0f8a500a-09b5-4dac-9142-d1d9cfda37c2.pdf) |
| 2026-08-14 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c70637dd-4bd8-4ae1-bc7b-f417713ad4ff.pdf) |
| 2026-08-13 | [Board Meeting Outcome for Outcome Of Board Meeting Held On August 13 2026 To Consider And Approve Inter-Alia Un-Audited Financial Results Of The Company For Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=98b2d1d4-fffb-4dc4-a5ff-039c3e490635.pdf) |
| 2026-08-05 | [Board Meeting Intimation for Consideration And Approval Of Inter Alia The Un-Audited Financial Results Of The Company For The Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e9dc0bf3-e017-46c3-a15f-703f81c2e920.pdf) |
| 2026-07-08 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=360ceb5d-23b1-4a23-b6d4-ca470eaf5fc6.pdf) |
| 2026-06-25 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=9e25318d-418b-4727-adb2-3a6b9d6b6226.pdf) |
| 2026-05-30 | [Compliances-Reg.24(A)-Annual Secretarial Compliance](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c2dad01-c8b1-4ace-b673-1e7617dda7bf.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-13 | [Outcome Of Board Meeting Held On August 13 2026 To Consider And Approve Inter-Alia Un-Audited Financial Results Of The Company For Quarter Ended June 30 2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c7b392d1-150d-4761-984f-257d8942e979.pdf) |
| 2026-05-29 | [Results- Financial Results For Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3ad393d0-adb5-4bbe-8d86-6769200e6284.pdf) |
| 2026-02-14 | [Results - Financial Results For 31/12/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=00c9bad2-fec4-4404-81e4-bf9e6b94c529.pdf) |
| 2025-11-14 | [Results For The Quarter/Half Year Ended 30/09/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f9049852-9b53-441f-8669-022ca68a070a.pdf) |
| 2025-08-13 | [Results For Quarter Ended 30.06.2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3c9f09e8-82cd-4af7-9b94-36d5745ca963.pdf) |
| 2025-05-28 | [AFR For The Qtr/Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=65b16cdc-50d2-44eb-bb2b-9d387dd8cae9.pdf) |
| 2025-05-26 | [AFR For The Quarter/ Year Ended 31/03/2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=594bbebe-5a66-4a99-b677-5df704c5b883.pdf) |
| 2025-02-12 | [UNAUDITED FINANCILA RESULTS FOR QUARTER ENDED DEC 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e761d6d1-09e7-4801-8e6e-ecba36e759b2.pdf) |
| 2024-11-14 | [Results For The Quarter Ended On 30.09.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f4c66185-f501-48ee-8f33-399b39955f69.pdf) |
| 2024-08-14 | [Result For The Quarter Ended 30/06/2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6e69457d-2768-4af6-9b83-79cac62e4ecf.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026. | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 7 Apr - Submitted Regulation 74(5) certificate for quarter ended 31 March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fc93616c-6c3f-46eb-b6e2-55c3ba91ddb3.pdf) |
| 6 Feb - Board meeting on 14 Feb 2026 to approve unaudited Q3 (31 Dec 2025) results; trading window closed till 16 Feb. | [Compliances-Reg. 50 (1) - Prior intimation about Board meeting under Regulation 50(1) 6 Feb - Board meeting on 14 Feb 2026 to approve unaudited Q3 (31 Dec 2025) results; trading window closed till 16 Feb.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/91612165-72ef-4b02-b546-93738210c212.pdf) |
| 5 Mar - Newspaper Advertisement for special window for transfer of physical shares. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 5 Mar - Newspaper Advertisement for special window for transfer of physical shares.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dfa14d95-05c6-40c3-a2e0-9779770ab7fa.pdf) |
| 30 Jan - Brawn Biotech appoints Ms. Rati Garg as Chief Financial Officer and KMP, effective 1 February 2026. | [Announcement under Regulation 30 (LODR)-Change in Management 30 Jan - Brawn Biotech appoints Ms. Rati Garg as Chief Financial Officer and KMP, effective 1 February 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1167f9d4-977e-4196-a7dd-bd09df30fa17.pdf) |
| 25 Mar - Appointed Mr. Viney as Secretarial Auditor and Sahil Pasricha & Associates as Internal Auditors, effective 25 Mar 2026, FY2025-26; Board approved. | [Board Meeting Outcome for ANNOUNCEMENT UNDER REGULATION 30 OF SEBI (LODR), 2015 25 Mar - Appointed Mr. Viney as Secretarial Auditor and Sahil Pasricha & Associates as Internal Auditors, effective 25 Mar 2026, FY2025-26; Board approved.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f20a1028-640a-4f14-a250-09ee1bb5e5da.pdf) |
| 19 Mar 2022 - Gateway Distriparks Limited (formerly known as Gateway Rail Freight Limited) has completed the process of getting the approval for listing and trading of the equity … | [Merger Updates- Trading Approval 19 Mar 2022 - Gateway Distriparks Limited (formerly known as Gateway Rail Freight Limited) has completed the process of getting the approval for listing and trading of the equity …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/925e4355-0166-408d-becf-1ba54d445e2a.pdf) |
| 16 Feb - Newspaper publication of Unaudited Financial Results for Quarter and year to date ended 31.12.2025. | [Announcement under Regulation 30 (LODR)-Newspaper Publication 16 Feb - Newspaper publication of Unaudited Financial Results for Quarter and year to date ended 31.12.2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/913ea996-83cd-48dc-9c71-c6f184fe08b8.pdf) |
| 14 Feb - Board approved unaudited Q3 and nine-month results for quarter ended 31 Dec 2025; limited review attached. | [Results - Financial Results For 31/12/2025 14 Feb - Board approved unaudited Q3 and nine-month results for quarter ended 31 Dec 2025; limited review attached.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/00c9bad2-fec4-4404-81e4-bf9e6b94c529.pdf) |
| 14 Feb - Board approved un-audited Q3 and nine-month results ended 31-Dec-2025; limited review report attached. | [Board Meeting Outcome for OUTCOME OF BOARD MEETING HELD ON TODAY 14 Feb - Board approved un-audited Q3 and nine-month results ended 31-Dec-2025; limited review report attached.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/634e5b4c-5059-401e-96fd-2fe36666fb38.pdf) |
| 13 Apr - Brawn Biotech confirms non-applicability of Large Corporate norms; outstanding borrowings nil as of 31 March 2025. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 13 Apr - Brawn Biotech confirms non-applicability of Large Corporate norms; outstanding borrowings nil as of 31 March 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c9580ebf-c396-4b82-b385-22d868e82f13.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2012 from nse](https://archives.nseindia.com/annual_reports/AR_GDL_2011_2012_31122012040707.zip) |
| from nse | [Financial Year 2011 from nse](https://archives.nseindia.com/annual_reports/AR_GDL_2010_2011_07092011121516.zip) |
| from nse | [Financial Year 2010 from nse](https://archives.nseindia.com/annual_reports/AR_GDL_2009_2010_05082011101125.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/28e846ec-cc5f-402c-b52f-67970e03abd5.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/5981592a-13e9-4fdc-8808-ba6c87cf4e63.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6ca4a544-156b-43b8-8e05-d4433c9ac562.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/530207/74814530207.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/532622/69353532622.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/530207/70392530207.pdf) |
| from bse | [Financial Year 2020 from bse](https://www.bseindia.com/bseplus/AnnualReport/532622/65676532622.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2020 | [Concall - Sep 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/89086179-85b8-4c55-9ef5-b98fff66a629.pdf) |
| Nov 2021 | [Concall - Nov 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ae5dde9d-ca6a-46ae-9217-61a7d2cd9e08.pdf) |
| May 2021 | [Concall - May 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f00b8093-722e-4be4-bce2-a35f017e8891.pdf) |
| Jun 2020 | [Concall - Jun 2020](https://www.bseindia.com/xml-data/corpfiling/AttachHis/156d677f-0735-4906-a510-63f728426aa6.pdf) |
| Jul 2021 | [Concall - Jul 2021](https://www.bseindia.com/xml-data/corpfiling/AttachHis/abb9c5ae-29db-4b3b-a8b1-7455022b3bc2.pdf) |
| Feb 2022 | [Concall - Feb 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/98533b0b-a7be-44fe-aef3-42f7ec1b2fd8.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:31:27.467Z.